Welcome to our dedicated page for CONCENTRA GROUP HOLDINGS PAREN SEC filings (Ticker: CON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Healthcare filings can feel like medical charts: dense, technical, and mission-critical. Concentra Group Holdings Parent Inc.’s disclosures weave together workers’ compensation statutes, telemedicine economics, and clinic utilization data—details investors hunt for yet rarely find quickly. If you have ever typed “Concentra Group Holdings Parent Inc. SEC filings explained simply” or searched for the next “Concentra Group Holdings Parent Inc. quarterly earnings report 10-Q filing,” you already know the challenge.
Stock Titan solves it. Our AI reads every line of the Concentra Group Holdings Parent Inc. annual report 10-K simplified, highlights segment profitability, and flags compliance risks in seconds. Need real-time alerts? We stream “Concentra Group Holdings Parent Inc. Form 4 insider transactions real-time,” so you can track executive stock transactions before the market reacts. Interactive dashboards turn pages of accounting notes into clear charts, while plain-English summaries answer the question: “What changed this quarter?”
The platform covers every filing type the moment it hits EDGAR: 10-K, 10-Q, 8-K material events explained, Form 4 insider trading transactions, and the proxy statement executive compensation breakdown. Use AI-powered summaries to compare clinic revenue trends, monitor workers’ comp claim costs, or assess telemedicine adoption—all without wading through footnotes. Whether you’re performing a Concentra Group Holdings Parent Inc. earnings report filing analysis or simply understanding Concentra Group Holdings Parent Inc. SEC documents with AI, our tools let you move from data to decision faster.
Concentra Group Holdings Parent, Inc. executive shares were adjusted in connection with equity compensation. On 11/26/2025, an officer identified as the Executive Vice President and Chief Medical Officer reported a Form 4 transaction in the company’s common stock. A total of 6,540 shares of common stock were disposed of at $21.04 per share under transaction code F, which indicates shares were withheld to cover tax obligations arising from the vesting of restricted stock.
After this tax withholding event, the reporting person directly beneficially owned 113,460 shares of Concentra Group Holdings Parent, Inc. common stock. The filing reflects an administrative adjustment related to equity compensation rather than an open‑market purchase or sale.
Concentra Group Holdings Parent, Inc. (CON)11/25/2025, the reporting person made a bona fide gift of 100,000 shares of common stock, shown with transaction code G and a price of $0 per share, which reflects the nature of a gift rather than a sale.
After this transaction, the director directly held 5,433,794 shares of common stock. The report also lists additional indirect beneficial ownership through several family trusts, including 1,023,455 shares held by The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio and 1,032,115 shares held by the Robert A. Ortenzio Descendants Trust, plus three 2014 trusts each holding 226,286 shares for individual beneficiaries.
T. Rowe Price Associates, Inc. filed an Amendment No. 2 to Schedule 13G reporting a passive stake in Concentra Group Holdings Par (CON). The firm reports beneficial ownership of 17,166,753 shares of common stock, representing 13.4% of the class, with the Date of Event listed as 09/30/2025.
The filing shows sole voting power over 16,959,244 shares and sole dispositive power over 17,166,753 shares; there is no shared voting or dispositive power. The certification states the securities were acquired and are held in the ordinary course and not to influence control. Within the reported holdings, T. Rowe Price Mid‑Cap Value Fund has an interest in 7,571,779 shares, or 5.9% of the class.
T. Rowe Price Investment Management, Inc. filed Amendment No. 1 to Schedule 13G reporting beneficial ownership of 6,267,949 shares of CONCENTRA GROUP HOLDINGS PAR common stock, representing 4.9% of the class as of 09/30/2025.
The firm reports sole voting power over 6,240,852 shares and sole dispositive power over 6,267,949 shares, with zero shared voting or dispositive power. The filing indicates the reporting person is an investment adviser (IA) and certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Concentra Group Holdings Parent, Inc. (CON) disclosed new executive equity awards. On November 4, 2025, the Board’s Human Capital and Compensation Committee granted restricted shares to the company’s named executive officers under the 2024 Equity Incentive Plan. These restricted stock awards vest in equal installments on each of the first four anniversaries of the grant date.
Grants by executive:
- W. Keith Newton: 225,000 shares
- Matthew T. DiCanio: 180,000 shares
- John A. deLorimier: 60,000 shares
- John Anderson: 60,000 shares
- Michael Kosuth: 60,000 shares
- Su Zan Nelson: 60,000 shares
The awards are time-based and align compensation with multi-year service and performance horizons via four-year ratable vesting.
Concentra Group Holdings Parent, Inc. (CON) reported a Form 4 showing an equity award to an executive. On 11/04/2025, the officer received 40,000 shares of restricted stock at $0. The grant will vest in equal annual installments over four years. After this transaction, the reporting person beneficially owned 80,098 shares, held directly. The executive’s title is Executive Vice President, Chief Operating Officer Onsite Health & Telemedicine.
Concentra Group Holdings Parent, Inc. (CON) reported an insider equity award. On 11/04/2025, a company officer received 60,000 shares of restricted stock at $0, increasing directly held common stock to 120,000 shares after the transaction. The award will vest in equal annual installments over four years.
The reporting person serves as Executive Vice President, Chief Operating Officer - East. This filing reflects a compensation grant rather than an open‑market purchase.
Concentra Group Holdings Parent, Inc. disclosed an officer equity award on Form 4. The President & Chief Financial Officer received 180,000 shares of restricted common stock on 11/04/2025 at a reported price of $0. The award will vest in equal annual installments over four years.
Following this grant, the officer’s beneficial ownership stands at 360,000 shares, held directly. This filing reflects routine executive equity compensation designed to align leadership with shareholders through multi‑year vesting.
Concentra Group Holdings Parent, Inc. reported a Form 4 showing an officer received a grant of 60,000 shares of common stock on November 4, 2025 at $0, increasing beneficial ownership to 120,000 shares, held directly. The award is restricted stock that vests in equal annual installments over four years. The officer’s title is Executive Vice President, Chief Clinical Services Officer.
Concentra Group Holdings Parent, Inc. (CON) disclosed a Form 4 showing a director acquired 7,748 shares of common stock as a restricted stock grant on November 4, 2025.
The restricted stock will vest in full on November 4, 2026, subject to certain exceptions. Following the transaction, the reporting person beneficially owns 74,000 shares directly. The grant was reported at a price of $0 per share.
FAQ
What is the current stock price of CONCENTRA GROUP HOLDINGS PAREN (CON)?
What is the market cap of CONCENTRA GROUP HOLDINGS PAREN (CON)?
